---
title: "CSPC PHARMA has received approval to conduct clinical trials for 3 products in mainland China"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/271044344.md"
description: "CSPC PHARMA announced that three of its products have been approved by the National Medical Products Administration to conduct clinical trials in China. Among them, the potent aldosterone synthesis inhibitor (SYH2072 tablets) is suitable for uncontrolled hypertension and primary aldosteronism; the ploglitazone dapagliflozin metformin extended-release tablets are used for blood sugar control in adult patients with type 2 diabetes; and the GLP-1/GIP receptor dual-bias agonist peptide injection (SYH2069 injection) is suitable for weight management in obese or overweight patients"
datetime: "2025-12-30T00:41:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271044344.md)
  - [en](https://longbridge.com/en/news/271044344.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271044344.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/271044344.md) | [繁體中文](https://longbridge.com/zh-HK/news/271044344.md)


# CSPC PHARMA has received approval to conduct clinical trials for 3 products in mainland China

According to a report from Economic Information Agency on the 30th, CSPC PHARMA (01093) announced that three products have been approved by the National Medical Products Administration to conduct clinical trials in China.

The group stated that the developed Class 1 new chemical drug, a potent aldosterone synthesis inhibitor (SYH2072 tablets), has been approved for clinical indications for uncontrolled hypertension and primary aldosteronism. As for the group's developed combination of ploglitazone, dapagliflozin, and metformin extended-release tablets, it has been approved for clinical indications for use in conjunction with diet and exercise in adults with type 2 diabetes who have inadequate blood glucose control with metformin hydrochloride alone.

In addition, the group indicated that the developed GLP-1/GIP receptor dual agonist peptide injection (SYH2069 injection) has been approved for clinical indications for weight management in populations with obesity or overweight with at least one weight-related comorbidity. (wh)

### Related Stocks

- [CSPC PHARMA (01093.HK)](https://longbridge.com/en/quote/01093.HK.md)

## Related News & Research

- [CSPC Pharma's Profit Falls 10% in 2025; Misses EPS, Revenue Estimates](https://longbridge.com/en/news/280415449.md)
- [Tranche Update on CSPC Pharmaceutical Group Limited's Equity Buyback Plan announced on September 19, 2024.](https://longbridge.com/en/news/280502605.md)
- [Hengrui Pharmaceuticals' Unit Gets Nod for HRS9531 Injection Clinical Trials](https://longbridge.com/en/news/280731966.md)
- [Yunnan Baiyao Gets Nod to Trial INB301 Injection](https://longbridge.com/en/news/281464510.md)
- [Huadong Medicine's Unit Gets Nod for HDM2024 for Injection's Clinical Trial](https://longbridge.com/en/news/280745131.md)